OSE Immunotherapeutics is narrowing its development activities after ending its collaboration with Boehringer Ingelheim on a candidate against MASH (metabolic dysfunction associated with hepatic steatosis).[1] Boehringer Ingelheim withdrew from the program because their joint SIRPα antagonist BI 770371 failed to demonstrate efficacy in a phase 2 study in patients with cirrhosis caused by MASH.[1] Boehringer will further develop this candidate in oncology, as monotherapy, in combination with a PD-1 inhibitor in advanced solid tumors, and as a potential first-line treatment in recurrent spinal cell carcinoma of the head and neck.[1] OSE will now focus on the cancer vaccine Tedopi and the advanced-stage anti-inflammatory drug lusvertikimab.[1] This is the second pipeline narrowing after December, when AbbVie returned the rights to the anti-inflammatory drug and OSE cut costs.[1] In addition, OSE is terminating CLEC-1 program research in oncology because it is not an immediate clinical priority.[1] The company will evaluate opportunities to maximize the value of the broader pipeline and is seeking funding for advanced clinical projects.[1]